Format

Send to

Choose Destination
J Nutr Health Aging. 2019;23(2):145-150. doi: 10.1007/s12603-018-1153-y.

The Effect of β-hydroxy-β-methylbutyrate (HMB) on Sarcopenia and Functional Frailty in Older Persons: A Systematic Review.

Author information

1
Prof. Gustavo Duque, MD, Ph.D., FRACP, FGSA, Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne and Western Health, 176 Furlong Road, St. Albans, VIC, Australia 3021,Tel: +61 3 8395 8121, Email: gustavo.duque@unimelb.edu.au.

Abstract

BACKGROUND:

Beta-hydroxy-beta-methylbutyrate (HMB) has been shown to be effective and superior to other types of protein supplements to attenuate loss of muscle mass, strength and function, however, its benefits in sarcopenic and frail older people remain unclear.

OBJECTIVE:

We seek to determine the effect of HMB on muscle mass, strength and function in older people with sarcopenia or frailty by reviewing results from available randomized controlled trials (RCTs).

DESIGN:

This review was registered at PROSPERO (University of York) with registration number CRD42018088462 and conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. Using a pre-determined e-search strategy, we searched PubMed, Medline, EMBASE, CINAHL, LILACS, Web of Science, Cochrane and Scopus databases. Our inclusion criteria were RCTs that assessed the effect of HMB on muscle mass, strength and function in older people with sarcopenia and frailty aged ≥60 years. The main outcomes were lean body mass, handgrip, leg press strength, and Short Physical Performance Battery (SPPB) score.

RESULTS:

Three studies matched our eligibility criteria which enrolled 203 subjects through a variety of definitions of sarcopenia or frailty. Lean body mass increased and muscle strength and function were preserved following HMB supplementation.

CONCLUSION:

HMB improves lean muscle mass and preserves muscle strength and function in older people with sarcopenia or frailty.

KEYWORDS:

Beta-hydroxy-beta-methylbutyrate; HMB; frailty; muscle; sarcopenia

PMID:
30697623
DOI:
10.1007/s12603-018-1153-y

Conflict of interest statement

The authors have no conflict of interest to declare

Supplemental Content

Loading ...
Support Center